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Edited by Gianni CesareniAbstract In previously proposed models of Ab soluble oligo-
mers, the N-terminal domain Ab1–16, which is missing in p3 pep-
tides, protects the hydrophobic core of the oligomers from the
solvent. Without this N-terminal part, oligomers of p3 peptides
would likely expose hydrophobic residues to water and would
consequently be less stable. We thus suggest, based on theoreti-
cal and experimental results, that p3 peptides would have a low
propensity to assemble into stable oligomers, evolving then di-
rectly to ﬁbrillar aggregates. These properties may explain
why p3 would be devoid of any impact on synaptic function
and moreover, strengthen the hypothesis that Ab oligomers are
the principal synaptotoxic forms of Ab peptides in Alzheimer dis-
ease.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Senile plaques, containing amyloid b peptides 1–40 and 1–42
(noted Ab1–40 and Ab1–42), characterize Alzheimers disease
(AD) pathology. In addition to Ab peptides, plaques also con-
tain amino-terminal truncated Ab peptides, including 3-kDa
fragments termed p3 peptide (corresponding to residues
Ab17–40 and Ab17–42). p3 peptides are derived from the
so-called ‘‘non-amyloidogenic’’ pathway of the amyloid
precursor proteins (APP) processing, by proteolytic activities
of a- and c-secretases [1,2].
Experiments have shown that ﬁbrillar Ab is composed of
cross-b structures [3–6]. Ab ﬁbril formation is preceded by var-
ious intermediates, water-soluble oligomeric states, and pro-
toﬁbrils peptide forms [7–11], which are suggested by
experimental and clinical ﬁndings to be particularly important
for the pathogenesis of AD [8,12]. Potential forms of these sta-
ble oligomeric soluble intermediates of Ab have been recently*Corresponding author. Fax: +33 2 31 02 22.
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doi:10.1016/j.febslet.2008.05.002modelled by homology with proteins sharing sequence similar-
ities with the Ab peptide [13,14].
Very few data on the structures of p3 are available in the lit-
erature. Dickson and colleagues [15] reported that p3 may rep-
resent a benign form of amyloid, since it lacks domains
associated with activation and recruitment of glia to senile pla-
ques. Higgins and colleagues [16] showed that p3 presents all of
the structural determinants required for ﬁbril assembly. Fur-
thermore, Pike and colleagues [17] observed in vitro that the
p3 fragment can adopt a b-sheet conformation and that ami-
no-terminal deletions of Ab peptide 1–16 enhance aggregation
of amyloid-b peptides. However, the importance of p3 peptide
accumulation in Alzheimer disease and its toxic properties are
still not clear. p3 peptide can assemble into ﬁbrils (for which
no speciﬁc models or structure are available) but, to our knowl-
edge, no oligomeric forms of p3 peptide have been identiﬁed.
In this study, we evaluate the eﬀect of a N-terminal trunca-
tion, leading to the p3 peptide, on the structure and stability of
models of Ab monomers and oligomeric soluble Ab assem-
blies, proposed in a previous work [13]. The propensity of p3
to form oligomeric intermediates was otherwise tested under
the same experimental conditions where Ab peptides form sol-
uble oligomers.2. Materials and methods
2.1. Molecular modelling
The coordinates of the three Ab models were retrieved from a previ-
ous work [13]. The construction of the p3-derived models was per-
formed using Swiss-PDB Viewer [18]. Models have been minimized
to energetic convergence using GROMOS96 through the Swiss-PDB
Viewer software [18]. This software has also been used to evaluate
the internal energy of each model. The solvent-exposed surface has
been calculated through the ASA program [19].2.2. Experimental materials
Human recombinant Ab1–42 was bought from Bachem (Weil am
Rhein, Germany) and p3 peptide (corresponding to Ab17–42) was
bought from Anachem (Luton, United Kingdom). For the Western
blot analysis of Ab conﬁguration, we used two mouse monoclonal
antibodies: 6E10, an antibody raised against residues 1–16 or 4G8
raised against residues 17–24 of Ab. 6E10 and 4G8 and all the other
chemicals were obtained from Sigma (LIsle dAbeau, France).2.3. Ab1–42 and p3 oligomerization and ﬁbrillogenesis
We used protocols of solubilisation of Ab and p3 described by Stine
et al. [20] that selectively induce oligomers or ﬁbrils formation of Ab.blished by Elsevier B.V. All rights reserved.
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pended in 1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP) to disrupt pre-
existent peptide aggregates [20]. The clear solution containing dis-
solved peptide was then aliquoted in microcentrifuge tubes. The HFIP
was then allowed to evaporate in a fume hood and resulted peptide
ﬁlms were stored at 80 C. Immediately prior to use, HFIP-treated
aliquots were carefully and completely resuspended to 5 mM in anhy-
drous dimethyl sulfoxide (DMSO) by pipette mixing and vortexing
[21]. Oligomers were prepared by diluting peptides to 100 lM in ice-
cold HEPES- and bicarbonates-buﬀered saline solution (HBBSS) with
immediate vortexing and sonication. Peptides were then incubated at
4 C for 24 h on a stirring machine. Fibrils were prepared by diluting
peptides to 100 lM in 10 mM HCl prepared in ultrapure water with
immediate vortexing and incubation at 37 C for 72 h on a stirring ma-
chine.
2.4. Western blot analysis of SDS–PAGE
Gel electrophoresis and Western blot analysis were performed
according to the manufacturers protocols (Invitrogen). Samples were
diluted in the NuPAGE LDS sample buﬀer and applied on a
4–12% NuPAGE bis-Tris SDS–PAGE gels. Electrophoresis was per-
formed using MES running buﬀer and transferred to polyvinylidene
diﬂuoride membranes (Polyscreen membrane, Perkin–Elmer, Paris,
France). Membranes were blocked in Tween 20, 0.1%-Tris 200 mM
buﬀered solution (TTBS) complemented with 5% bovine serum albu-
min (BSA) during 1 h and blots were incubated at 4 C overnight un-
der gentle agitation with the indicated antibody (1:1000). Incubation
with the secondary peroxidase-conjugated anti-rabbit (1:50000) anti-
bodies was performed during 1 h at room temperature. Finally, blots
were detected with an enhanced chemiluminescence Western blottingFig. 1. Molecular models of Ab and p3 soluble oligomers. (A) Ribbon diagra
monomeric and hexameric and TTR-based (3) monomeric and tetrameric Ab
strands (adhesin and SFVP-based models), which is truncated in p3, is color
diagrams of the adhesin-based (1) monomeric and tetrameric, SFVP-based
tetrameric p3 models. The two b-strands which compose the b-hairpin are co
Molecular surface of the p3 monomeric and oligomeric models with the su
green. This ﬁgure was made using Swiss-PDB-Viewer.detection system (Western Lightning Chemiluminescence Reagent
Plus, Perkin–Elmer). Molecular weight values were estimated using
the Seeblue Plus2 pre-stained standard molecular weight marker
(Invitrogen).3. Results
3.1. Description of the Ab soluble oligomeric models
In our previous work [13], we have constructed three struc-
tural models for Ab1–42 soluble oligomers on the basis of se-
quence similarity with fragments of three functionally
unrelated proteins: the DraE adhesin, the serine protease mod-
ule of Semliki Forest virus (SFVP) and the transthyretin
(TTR). These potential structurally similar fragments have
been identiﬁed by searching in the Protein Data Bank (PDB)
[22] for sequence similarities that could be validated at the
two-dimensional level using the ‘‘Hydrophobic Cluster Analy-
sis’’ (HCA) method [23]. The three monomeric models were
constructed on the basis of the alignment of each template with
the sequence of the Ab peptide and using MODELLER [24].
The adhesin-based model, extracted from an immunoglobu-
lin-like domain, is composed of four antiparallel b-strands
forming two two-stranded b-sheets (Fig. 1, 1A). The SFVP-
based model, extracted from a b-barrel, displays four b-strands
(Fig. 1, 2A). The TTR-based model consists in three main b-ms of the adhesin-based (1) monomeric and tetrameric, SFVP-based (2)
models. The N-terminal domain with one (TTR-based model) or two b-
ed in orange and the C-terminal domain is colored in grey. (B) Ribbon
(2) monomeric and hexameric and TTR-based (3) monomeric and
lored in red (central b-strand) and in green (C-terminal b-strand). (C)
rface corresponding to hydrophobic residues (VILFMYW) colored in
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sheet with its neighbour b-strand (Fig. 1, 3A). These Ab mod-
els share a similar structure in the C-terminal region forming a
b-hairpin composed of two b-strands (called the central and
the C-terminal ones), which are connected by a loop. This b-
hairpin is stabilized by a salt bridge between Asp23 and
Lys28 which also exists in the ﬁbrillar form of the Ab peptide
[4]. This conformation, which would form the stable core of
the Ab monomer, is relatively close to the Ab structure core
elements observed within Ab ﬁbrils and these two b-strands
have been shown to be key determinants for ﬁbrillogenesis
[25–27]. The N-terminal part of Ab (orange in Fig. 1, line
A), which is diﬀerent in the three models, is modelled by two
b-strands in the adhesin and SFVP-based models and by one
b-strand in the TTR-based model. These monomeric models
of Ab expose hydrophobic patches to the solvent, which make
them thermodynamically unfavourable entities. In order to
bury most of these hydrophobic amino acids, we constructed
more stable oligomers (dimer/tetramer and trimer/hexamer
for the adhesin and SFVP-based models, respectively). As
the TTR template fragment used for the Abmodelling is impli-
cated in the formation of dimer and tetramer in TTR, we con-
sidered these native oligomers of TTR to construct dimer and
tetramer of the Ab peptide. In these three models, the b-hair-
pin constitutes the hydrophobic core of the oligomers which is
always protected by the hydrophilic N-terminal domain of the
Ab peptide. These water-soluble oligomeric models might sam-
ple the possible conformations of the experimentally observed
multimeric Ab assemblies [13].
3.2. Eﬀect of a N-terminal truncation on the Ab models, leading
to p3 peptide
The eﬀect of the lack of the N-terminal segment in p3 rela-
tive to Ab on the structure and stability of the peptide was con-
sidered by truncating the N-terminal domain (residues 1–16) of
the Ab1–42 monomeric models (orange in Fig. 1, line A). Fol-
lowing these constructions, p3 peptides would be limited to
the b-hairpin (red and green in Fig. 1, line B), which is well
conserved between the three proposed Ab soluble models. This
b-hairpin exposes many hydrophobic residues (in green on
monomers surface in Fig. 1, line C) with only one hydrophilic
patch on the D23–K28 loop.
To construct p3 oligomers, we assembled monomers in var-
ious ways and try to burry most of the hydrophobic amino
acids. Whatever assemblies we built, the resulting oligomers al-
ways exposed to solvent the hydrophobic b-hairpin core, and
present a high positive energy. In order to evaluate the stability
of p3 oligomeric forms compared to those of Ab, we have built
the p3 models (Fig. 1, line B) based on the tetrameric and hex-
americ models of Ab (Fig. 1, line A). The absence of the N-ter-
minal segment of Ab, which protects the hydrophobic core ofTable 1
Final minimized energies (kJ/mol), percentage of solvent-exposed hydrophobi
three oligomeric models of Ab and the corresponding p3 oligomeric models,
hydrophobic surfaces or reduction of buried surface area between the Ab an
Energy (kJ/mol) % Hydro
Ab models p3 models Ab mod
Adhesin-based 4553 858 43
SFVP-based 3583 837 33
TTR-based 3348 512 44the Ab oligomers from solvent, makes these Ab-based oligo-
meric models of p3 unstable (tetramers and hexamers in Fig.
1, line C).
We calculated the ﬁnal minimized energies of the oligomeric
forms of Ab and p3 (Table 1). The p3 oligomeric models are all
characterized by a positive energy, whereas all Abmodels pres-
ent a strong negative one. Then, we compared the proportion
of hydrophobic residues accessible to solvent (colored in green
in Fig. 1, line C) in p3 and Ab models. The solvent-exposed
hydrophobic surfaces increased in the p3 peptide compared
to the Ab oligomeric forms from 20% to 60% (Table 1)
and the buried surface areas within the oligomers are logically
smaller in p3 compared to Ab (from 30 to 50%; Table 1).
In conclusion, the estimated energy of the Ab-based oligo-
meric models of p3 is always positive, the models expose
hydrophobic patches to the solvent and bury a small propor-
tion of their accessible surface within the oligomeric intermedi-
ates, which render their existence thermodynamically
unfavourable. We thus hypothesized that the p3 peptide can-
not form stable soluble oligomers in the same way as Ab does.
3.3. Experience shows that p3 peptides do not form oligomeric
intermediates but mainly ﬁbrils
To validate this hypothesis, we performed Western blot
analysis on the diﬀerent human peptides Ab1–42 or p3 incu-
bated in either oligomers-forming conditions during 24 h at
4 C in a solution with physiologic pH and ionic strength or
in ﬁbrils-forming conditions during 72 h at 37 C in 10 mM
HCl [20]. Ab oligomers appear to be relatively stable struc-
tures, as SDS-resistant species have been isolated from post-
mortem human brains and cell lines [28,29]. We determined
whether SDS-resistant Ab oligomers could be identiﬁed and
resolved by SDS–PAGE and Western blotting from these
experimental solutions. The Immunoblots were incubated with
Ab monoclonal antibodies 6E10, recognizing Ab 1–16 residues
and 4G8, recognizing Ab 17–24 residues.
In oligomers-forming conditions, both primary antibodies
revealed the presence of monomers, dimers, trimers and tetra-
mers of Ab1–42 (Fig. 2, lanes 1 and 3) and high molecular
weight oligomers (especially with the primary antibody
6E10). In ﬁbrils-forming conditions, we observed the presence
of monomers and dimers (with 4G8) but no tetramers. A
fainted signal revealed a moderate presence of high molecular
weight oligomers, while most of Ab1–42 were converted in high
molecular weight ﬁbrils that remained in the well.
p3 peptide blots revealed with the primary antibody 6E10,
recognizing Ab1–16 residues, did not show any signal as
expected (data not shown). With 4G8, synthetic human p3
peptide exposed to oligomers or ﬁbrils-forming conditions
exhibits a very similar electrophoretic migration proﬁle
showing only monomers without any low molecular weightc surfaces and buried surface within oligomers (A˚2 per monomer) of the
with the percentages of increase of the percentage of solvent-exposed
d p3 oligomers within brackets
phobic surface Buried surface (A˚2)
els p3 models Ab models p3 models
53 (+23) 1570 748 (52%)
54 (+64) 796 538 (32%)
58 (+32) 511 266 (48%)
Fig. 2. Western blot analysis of human Ab1–42and p3 under oligomers or ﬁbrils-forming conditions. Western blot analysis of SDS–PAGE were
performed on blots incubated in the primary antibody 6E10 (mouse monoclonal against Ab residues 1–16) or 4G8 (mouse monoclonal against Ab
residues 17–24). Blots revealed Ab1–42 monomers, dimers, trimers, tetramers and large oligomeric assemblies ranging from 30 to 70 kDa for samples
incubated under oligomers-forming conditions (lanes 1 and 3). Smearing between tetramer and monomer, may indicate interconversion between
these assemblies during electrophoresis (lane 1). Ab1–42 samples incubated under ﬁbrils-forming conditions contained high molecular weight
immunoreactive Ab that remained in the well, less abundant large oligomers (mostly detected with 6E10, lane 2), dimer and monomer (with 4G8, lane
4). In oligomers-forming conditions, 4G8 revealed an abundant tetramer band which was not detected under ﬁbrils-forming conditions, although
dimers and monomers were present in both conditions. p3 samples incubated under oligomers or ﬁbrils-forming conditions only contained monomers
(lanes 5 and 6), while high molecular weight ﬁbrils remain in the well.
1868 F. Dulin et al. / FEBS Letters 582 (2008) 1865–1870oligomers (Fig. 2, lanes 5 and 6). As for Ab, high molecular
weight ﬁbrils remain in the well.
In conclusion, Western blot analysis conﬁrms that trunca-
tion of 1–16 prevents the formation of stable oligomers, sug-
gesting that the N-terminal 1–16 residues of Ab1–42 are
essential for the formation of stable, water-soluble oligomeric
intermediates.4. Discussion–conclusion
The hydrophilic N-terminal amino acids 1–16 of Ab1–42,
does not belong to the b-sheet network of the Ab ﬁbril, since
this portion of the peptide in the ﬁbril is ﬂexible [30], insensi-
tive to replacement by proline [31], and suﬃciently exposed
in the amyloid ﬁbrils to account for rapid protease digestion
in protease digestion experiments [32]. These data suggest that
this N-terminal region is too disordered to be part of the
tightly packed b-sheet in the ﬁbrils. Heparan sulfate proteogly-
cans [33], metals like Al(III), Fe(III), Zn[5] and Cu[5] [34–36]
or proteins like CLAC (‘‘Collagen-like Alzheimer amyloid pla-
que component’’) [37] bind to residues which are located in this
region. Within the models of Ab soluble oligomers we have re-
cently proposed [13] that the N-terminal domain, modelled by
one or two b-strands, is always accessible to solvent, which is
consistent with available experimental data.We suggest here that the p3 oligomers could not durably ex-
ist by themselves, and quickly evolved to ﬁbrillar forms, where
the exposed hydrophobic patches are buried. This hypothesis is
strengthened by the experimental ﬁnding that solution of p3
exposed to oligomers-forming conditions does not assemble
into stable oligomers but only into ﬁbrils, whereas Ab1–42 in
the same concentration does. Our results are in agreement with
those of Pike and colleagues [17] who observed that amino-ter-
minal deletions of Ab peptide 1–16 enhance aggregation of
amyloid-b peptides. Similarly to the Ab1–42 peptide, p3 peptide
inserted in the membrane, is likely to be in helical conforma-
tion. We thus propose that, after cleavage by the a- and c-sec-
retases and extraction from the membrane, the a helical p3
peptide would quickly adopt a b-hairpin conformation. This
p3 monomer, highly hydrophobic, would rapidly evolve to ﬁ-
brils with no soluble intermediates forms.
Ab peptides are believed to have a causative role in the path-
ogenesis of Alzheimer disease. Because Ab assembles into a
variety of higher-order structures that include low molecular
weight oligomers, protoﬁbrils and ﬁbrils, questions have
emerged on the neurotoxic potential of these structures. If
ﬁbrillar forms of Ab that are present in the amyloid plaques
are neurotoxic in primary neuronal culture, the relatively weak
correlations between ﬁbrillar plaque density and severity of
dementia led to a re-evaluation of the role of soluble Ab olig-
omers in Alzheimer disease pathophysiology. Several studies
F. Dulin et al. / FEBS Letters 582 (2008) 1865–1870 1869plead for the implication of soluble Ab in cellular disturbance
observed in Alzheimer disease. Indeed strong correlations be-
tween soluble Ab levels and the extent of synaptic loss and/
or cognitive impairment have been demonstrated [28]. Further,
more studies have revealed that soluble oligomeric forms of Ab
are involved in the disruption of synaptic plasticity and toxic-
ity in vitro and in vivo [8,38]. Because p3 is generated through
the so-called non-amyloidogenic pathway, only few studies
have been speciﬁcally designed to evaluate its impact on neuro-
nal function. However, Wash et al. [29] have used p3 peptide
solution to rule out the possible role of this truncated Ab on
synaptic plasticity. They revealed that p3 solution are devoid
of any impact on synaptic function [29]. In the present study,
we demonstrate that human p3 peptide in solution cannot
form stable oligomeric intermediates, as human Ab does.
The impossibility to form p3 stable soluble oligomers com-
bined to the absence of impact on synaptic function of p3 solu-
tion revealed by Walsh and colleagues [29] may be interpreted
as a new set of data that highlighted the role of soluble oligo-
mers in the amyloid-b mediated synaptotoxicity.
In conclusion, by using a combine theoretical and experi-
mental approach, we demonstrated that the intuitive evidence
of the absence of implication of the non-amyloidogenic pro-
cessing of APP in the physiopathology of Alzheimer disease
may rely on the impossibility to form stable soluble oligomers
from the truncated form of Ab1–42: the p3 peptide.References
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